All Eyes On China As Market Activity Heats Up
This article was originally published in PharmAsia News
Mergers and acquisitions in China’s life sciences industry are ramping up, with some segments, such as the orthopedic device space, particularly hot. As Chinese companies rise with the market, alliance deals are increasing sharply and financing deals remain stable, according to EBI’s Strategic Transactions database.
You may also be interested in...
Wright Medical’s decision to sell its hip and knee business wasn’t entirely unexpected. The buyer, the Chinese company MicroPort, may have surprised some, but changes in orthopedics and the device industry as a whole could make such deals more common.
HONG KONG - China's second-largest drug distributor plans to issue shares in Hong Kong in less than a year as it builds up its acquisitions war chest
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.